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Background: Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, has been shown to possess pleiotropic effects
including body weight reduction. However, long-term effect of liraglutide on body weight and glycemic control
has not been elucidated in Japanese type 2 diabetes (T2D) subjects. Present study investigates whether liraglutide
treatment maintains the body weight-decreasing and glucose-lowering effects for 2 years in Japanese T2D subjects.
Methods: The enrolled subjects were 86 T2D patients [age; 59.8 ± 12.8 years, duration of diabetes; 15.8 ± 9.5 years,
glycated hemoglobin (HbA1c); 8.5 ± 1.5%, body mass index (BMI); 27.3 ± 5.4 kg/m2 (15.8 - 46.5 kg/m2), mean ± SD].
Among 86 subjects, liraglutide was introduced in 25 inpatients and 61 outpatients, and 46 subjects were followed for
2 years. Clinical parameters were measured at baseline and 3, 6, 9, 12, and 24 months after liraglutide introduction. The
increase in liraglutide dosage and the additional usage of glucose-lowering agents depended on each attending physician.
Results: At 1 year after liraglutide introduction, 69 patients (80.2%) decreased body weight and 58 patients (67.4%)
improved glycemic control. Body mass index (BMI) was changed 27.3 ± 5.4 kg/m2 to 25.9 ± 4.8 kg/m2 and percent
reduction of body weight was significant and maintained over 4% at 2 years after liraglutide introduction. HbA1c was
significantly decreased from 8.5 ± 1.5% to 7.7 ± 1.2% for 2 years. Liraglutide treatment tended to ameliorate lipid profile
and hepatic enzymes. Stepwise regression analysis demonstrated that baseline BMI and previous insulin dose were
positively associated with body weight reduction and baseline HbA1c was positively associated with reduction of
HbA1c at 2 years after liraglutide introduction.
Conclusions: Long-term liraglutide treatment effectively maintained the reduction of body weight and the fair
glycemic control, and also improved lipid profile and liver enzymes in Japanese T2D subjects.
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Recently, systematic analysis for the global prevalence of
overweight and obesity has reported that the proportion
of overweight adults gradually increased between 1980
and 2013 from 28.8% to 36.9% in male and from 29.8%
to 38.0% in female [1]. The prevalence of type 2 diabetes
has also increased worldwide [2] and similar increase* Correspondence: norikazu_maeda@endmet.med.osaka-u.ac.jp
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unless otherwise stated.was observed in Asia including Japan [3]. Evidently,
obesity, especially visceral fat obesity, is located up-
stream of type 2 diabetes, hypertension, dyslipidemia,
and atherosclerosis [4]. Obese type 2 diabetes subjects
are more liable to cardiovascular diseases. Indisputably,
the effective and efficient therapeutic strategy for obese
type 2 diabetes should be developed and promoted. It is
clear that the weight reduction is a therapeutic basis for
obese type 2 diabetes. However, the management for
obese type 2 diabetes often encounters difficulty in the
control of appetite and body weight. In addition, treatmenttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Baseline characteristics
Sex (Male/Female) 44/42
Age (years) 59.8 ± 12.8
Duration of diabetes (years) 15.8 ± 9.5
HbA1c (%) 8.5 ± 1.5
Body mass index (kg/m2) 27.3 ± 5.4
Waist circumference (cm) 100.2 ± 11.3
LDL-C (mg/dL) 108.9 ± 33.4
HDL-C (mg/dL) 47.2 ± 13.8











Data are mean ± SD or number of subjects. LDL-C; low-density lipoprotein-
cholesterol, HDL-C; high-density lipoprotein-cholesterol, BG; biguanide, SU;



































Figure 1 Scatter plot of changes in body weight and HbA1c
from baseline to 1 year after liraglutide introduction.
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times increase adiposity and such anti-diabetic treatments
incidentally result in poor glycemic control because of
weight gain.
Glucagon-like peptide-1 (GLP-1) is an incretin hor-
mone with a potent blood-glucose lowering action only
during hyperglycemia by inducing insulin secretion and
reducing glucagon secretion in a glucose-dependent
manner [5]. Beyond glucose-lowering effect, GLP-1 de-
lays gastric emptying and induces satiety, leading to
weight reduction. The mechanism is partly explained by
the combination effects of GLP-1 on the gastrointestinal
tract and the brain [6]. Native GLP-1 is immediately de-
graded and its elimination half-life is 1–2 min, whereas
liraglutide has a long half-life, around 13 hours, and can
be administered once a day [7]. A series of Liraglutide
Effect and Action in Diabetes (LEAD) study showed the
significant effect of liraglutide on weight reduction as
well as glycemic control mainly in Caucasian diabetes
subjects. Recently, long-term efficacy of liraglutide on
weight reduction has been demonstrated in the sub-
analyses of LEAD study [8,9]. Our group has indicted
the beneficial effects of liraglutide on visceral fat adipos-
ity, body weight, and eating behavior until 6 months
after liraglutide initiation in Japanese obese type 2 dia-
betes subjects [10,11]. However, it has not been eluci-
dated in Japanese type 2 diabetes subjects whether the
effect of liraglutide on body weight and glycemic control
would be maintained for longer period.
In Japanese type 2 diabetes subjects, we herein investi-
gated the effects of liraglutide on body weight and gly-
cemic control, and analyzed the association of clinical
parameters and changes in body weight and HbA1c for
2 years after liraglutide introduction.
Materials and methods
Subjects
Present study was an observational study and the inclu-
sion criteria were the subjects who were type 2 diabetes,
introduced with liraglutide therapy at Osaka University
Hospital (Osaka, Japan) between November 2010 and
December 2012, and continued liraglutide treatment
over one year. Number of subjects who were initiated
with liraglutide during the indicated period was 136 dia-
betes patients. Among 136 patients, 22 patients returned
to their home doctor, and thus 114 patients were
followed up by our hospital. The 28 patients discontin-
ued the liraglutide treatment within one year because of
the following reasons: 11 patients suffered complications
(digestive symptoms, severe loss of appetite, headache,
and vertigo), 2 patients significantly improved glycemic
control and discontinued liraglutide treatment, 14 pa-
tients deteriorated glycemic control and changed liraglu-
tide treatment to other anti-diabetic agents, and 1patient was diagnosed colon cancer. We finally analyzed
86 subjects who continued liraglutide treatment over
one year, and 46 subjects were followed for 2 years
among them. Among 86 subjects, 25 patients were intro-
duced liraglutide during hospitalization and 61 patients
were initiated liraglutide as an ambulatory treatment.
Physical examination and various metabolic parame-
ters were measured at baseline and 3, 6, 9, 12, and
24 months after liraglutide introduction. Briefly, waist
Inoue et al. Diabetology & Metabolic Syndrome 2014, 6:95 Page 3 of 9
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late expiration phase at standing position by using a
non-stretchable tape. Blood pressure was examined by
using an aneroid sphygmomanometer at sitting position
under resting condition in the consultation room. The
increase in liraglutide dosage (0.3 mg/day, 0.6 mg/day or
0.9 mg/day, representing the maximum dose used in
Japan) and the additional usage of glucose-lowering
agents was depended and decided by each attending
physician. The study protocol was approved by the hu-
man ethics committee of Osaka University and was reg-
istered with the University hospital Medical Information
Network (Number: UMIN 000004192), and the in-
formed consent was obtained from study subjects.Table 2 Correlations between baseline parameters and the re


















Insulin dose 0.266 0.016
Insulin dose U/kg 0.213 0.055









Reduction of body weight or HbA1c from baseline to 1 year was analyzed with bas
BMI; body mass index, WC; waist circumference, DM; diabetes mellitus, SBP; systolic
HbA1c; glycated hemoglobin, LDL-C; low-density lipoprotein-cholesterol, TG; triglycerid
ALT; alanine aminotransferase, sCPR; serum C-peptide immunoreactivity, BG; biguanide
dipeptidyl peptidase-4 inhibitor.Questionnaire for eating behavior
Eating behavior was assessed in part of patients before
liraglutide treatment by using the questionnaire of The
Guideline For Obesity issued by the Japan Society for
the Study of Obesity. As reported previously [10], this
questionnaire consists of 55-item questions of seven
major scales as follows: 1) Recognition for weight and
constitution (e.g.,‘Do you think it is easier for you to gain
weight than others?’), 2) External eating behavior (e.g., ‘If
food smells and looks good, do you eat more than
usual?’), 3) Emotional eating behavior (e.g., ‘Do you have
the desire to eat when you are irritated?’), 4) Sense of
hunger (e.g. ‘Do you get irritated when you feel hun-
































body pressure; DBP diastolic body pressure, FPG; fasting plasma glucose,
es, HDL-C; high-density lipoprotein-cholesterol, AST; aspartate aminotransferase,
, SU; Sulfonylurea, αGI; α-glucosidase inhibitor, TZD; thiazolidinedione, DPP4i;
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http://www.dmsjournal.com/content/6/1/95preference (e.g., ‘Do you like meat?’), 7) Regularity of eat-
ing habits (e.g., ‘Is your dinner time too late at night?’).
All items were rated on a four-point scale ranging from
1 (seldom) to 4 (very often).Statistical analysis
Data of two groups were compared by the Student’s t-
test or the Mann–Whitney test. The frequencies were
compared between two groups by the χ2 test. The corre-
lations between body weight, HbA1c and other parame-
ters were first analyzed by simple regression analysis and
then by multivariate stepwise analysis. In all cases, p
values <0.05 were considered statistically significant. AllTable 3 Baseline parameters and the reduction of body weigh


















Insulin dose 0.105 0.555
Insulin dose U/kg 0.015 0.933









Reduction of body weight or HbA1c from baseline to 1 year was analyzed with bas
altered except dosage of liraglutide.
BMI; body mass index, WC; waist circumference, DM; diabetes mellitus, SBP; systolic
HbA1c; glycated hemoglobin, LDL-C; low-density lipoprotein-cholesterol, TG; triglycerid
ALT; alanine aminotransferase, sCPR; serum C-peptide immunoreactivity, BG; biguanide
dipeptidyl peptidase-4 inhibitor.analyses were performed with the JMP Statistical Discov-
ery Software 8.0 (SAS Institute, Cary, NC).Results
Characteristics of participants
Table 1 shows the baseline characteristics of 86 subjects
before liraglutide introduction. The mean age and body
mass index (BMI) were 59.8 years and 27.3 kg/m2, re-
spectively, and BMI ranged from 15.8 to 46.5 kg/m2.
Fifty-nine subjects (69%) were obesity in Japanese cri-
teria (BMI ≥ 25 kg/m2). The duration of diabetes was
15.8 years and the mean hemoglobin A1c (HbA1c) was





p valuer p value
−0.147 0.401
−0.053 0.764























eline clinical parameters in 35 subjects whose anti-diabetic agents were not
body pressure; DBP diastolic body pressure, FPG; fasting plasma glucose,
es, HDL-C; high-density lipoprotein-cholesterol, AST; aspartate aminotransferase,














































Figure 2 Changes in body weight and HbA1c for 2 years after
liraglutide introduction. A, % Change of body weight. B, Change
in HbA1c. Data are mean ± SE of 86 patients (0, 3, 6, 9, and
12 months) or 46 patients (24 months). **P < 0.01, ***P < 0.001,
compared with the values at 0 month.
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of patients were treated with insulin (average dosage:
26.9 units/day, maximum dosage: 93 units/day). These
parameters indicate that the enrolled patients had rela-
tively long duration of diabetes, relatively high frequency
of obese subjects, high frequency of insulin use, and high
dosage of insulin.
Patients were introduced with liraglutide treatment
from 0.3 mg/day and its dosages were gradually in-
creased according to glycemic control level by attending
physicains. The number of patients treated with liraglutide
at 0.3, 0.6, and 0.9 mg/day was 7, 24, and 55 patients at
1 year after liraglutide introduction, respectively, and such
number of patients was 2, 8, and 36 patients at 2 year after
liraglutide introduction, respectively.
Changes of body weight and HbA1c at 1 year after
liraglutide introduction
In Figure 1, the individual changes in body weight and
HbA1c from baseline to 1 year are shown as a scatter
plot. The number of patients who reduced body weight
was 69 cases (80.2%), and that of who improve glycemic
control was 58 patients (67.4%). Forty-six patients (53.5%)
were located in the lower left quadrant, i.e. both body
weight and HbA1c were decreased in these patients.
Table 2 summarizes correlation analyses for the reduc-
tion of body weight or HbA1c from baseline to 1 year
with baseline clinical parameters. Body weight reduction
was associated positively with baseline BMI, aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
baseline insulin dose, and previous insulin use. Stepwise
regression analysis demonstrated that baseline BMI (P =
0.007) and previous insulin use (P = 0.027) were signifi-
cantly and independently correlated with body weight re-
duction at 1 year. Reduction of HbA1c was associated
positively with baseline HbA1c and negatively with insulin
use for previous treatment. Lipids such as low-density
lipoprotein-cholesterol (LDL-C) and triglyceride (TG)
tended to be correlated with change in HbA1c. Stepwise
regression analysis demonstrated that baseline HbA1c
(P < 0.001) was correlated significantly and independ-
ently with the reduction of HbA1c.
To exclude the effect of other anti-diabetic agents on
body weight and glycemic control, we collected 35 pa-
tients whose anti-diabetic agents except liraglutide were
not altered from baseline to 1 year (Table 3). Reduction
of body weight was correlated significantly and positively
with baseline BMI, ALT and the scores of the question-
naire for eating behavior, and was correlated negatively
with systolic blood pressure. Stepwise regression analysis
demonstrated that baseline BMI tended to be associated
with body weight reduction. Reduction of HbA1c was
correlated positively with baseline BMI, HbA1c, LDL-C,
TG, and ALT, and negatively with baseline HDL-C andprevious insulin use. However, there were no significant
associations with the reduction of HbA1c and the base-
line clinical parameters by stepwise regression analysis.
Changes in body weight, HbA1c, lipid profile and hepatic
enzymes for 2 years
The 46 patients who continued to be treated with lira-
glutide over 2 years were next analyzed. BMI at 0, 3, 6,
9, 12, and 24 months were 27.3 ± 5.4, 26.3 ± 4.9, 25.8 ±
5.1, 25.9 ± 5.9, 25.8 ± 5.0, and 25.9 ± 4.8 kg/m2, respect-
ively. Percent change in body weight indicated that body
weight was significantly reduced and its reduction was
maintained over 4% for 2 years (Figure 2A). HbA1c was
significantly reduced at 3 months (7.4 ± 1.1%), and tended
to increase at 6, 9, 12, and 24 months (7.7 ± 1.3%, 7.7 ±
1.3%, 7.8 ± 1.4%, and 7.7 ± 1.2%, respectively). Significant
decrease of HbA1c was observed until 2 years after liraglu-
tide introduction, compared to baseline HbA1c (Figure 2B).
Lipids (Figure 3) and hepatic enzymes (Figure 4) were
also measured. LDL-C level was significantly reduced at 6
and 12 months, while high-density lipoprotein-cholesterol
(HDL-C) tended to increase at 12 months (P = 0.098 ver-
sus 0 month). There were no significant changes of TG
level from 0 to 24 months. AST level was significantly re-
duced at 3 months and tended to decrease at 12 months

































Figure 4 Changes in liver enzymes for 2 years after liraglutide
introduction. Data are mean ± SE of 86 patients (0, 3, 6, 9, and
12 months) or 46 patients (24 months). AST, aspartate aminotransferase;





















































Figure 3 Changes in lipids for 2 years after liraglutide
introduction. Data are mean ± SE of 86 patients (0, 3, 6, 9, and
12 months) or 46 patients (24 months). LDL-C, low-density lipoprotein-
cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein-cholesterol.
*P < 0.05, compared with the values at 0 month.
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0.054 versus 0 month).
Correlation of baseline clinical parameters with the
reduction of body weight or HbA1c at 2 years
Table 4 summarizes correlation analyses for the reduc-
tion of body weight or HbA1c from baseline to 2 years
with baseline clinical parameters. Reduction of body
weight was positively correlated with baseline BMI, waist
circumference (WC), and insulin dose. Stepwise regres-
sion analysis demonstrated that baseline BMI and insulin
dose was significantly associated with body weight re-
duction for 2 years. Reduction of HbA1c was correlated
positively with baseline HbA1c and LDL-C, and it was
correlated negatively with sulfonylurea use for previous
treatment. Stepwise regression analysis demonstrated
that baseline HbA1c was significantly associated with
the reduction of HbA1c.
Discussion
We demonstrated that liraglutide treatment decreased
body weight and visceral fat adiposity, and ameliorated
eating behavior until 6 months after liraglutide initiationin Japanese obese type 2 diabetes subjects [10,11]. How-
ever, further long-term effect of body weight reduction
and glycemic control by liraglutide has not been exam-
ined in Japanese type 2 diabetes subjects. Present study
for the first time demonstrates the efficacy of liraglutide
on weight reduction and fair glycemic control over
2 years in Japanese type 2 diabetes subjects. There are
few reports describing the effect of liraglutide on body
weight over 2 years. The LEAD-3 sub-analysis showed
the significant weight reduction by liraglutide treatment
for 2 years [8]. As shown in Figure 2A, liraglutide treat-
ment for 2 years resulted in the 4.7% weight reduction
(decrease of body weight: −3.4 kg from baseline).
Present study suggests that over 4% of long-term body
weight reduction can be expected by the low dose lira-
glutide treatment for Japanese patients, even with the
additional other anti-diabetic agents causing weight gain
such as insulin and sulfonylurea.
Evidently, the control of food intake cannot be ignored
in the treatment of obese type 2 diabetes, but it is often
difficult to control appetite and reduce adiposity in
obese subjects. GLP-1 delays gastric emptying and in-
duces satiety, which is probably related to the combined
effect of GLP-1 on the gastrointestinal tract and the
brain [12,13]. Peripheral administration of liraglutide or
lixisenatide can cross the blood brain barrier and en-
hanced cAMP level in brain, suggesting that GLP-1 re-
ceptor agonists directly acts on central nerve system
[14]. Gastrointestinal and central nervous effect of GLP-
Table 4 Correlations between baseline parameters and the reduction of body weight or HbA1c at 2 year




p valuer p value r p value
Age −0.080 0.601 −0.197 0.190
Male −0.131 0.390 −0.052 0.732
BMI 0.474 0.001 0.018 0.134 0.382
WC 0.111 0.012 0.255 0.055 0.776
Duration of DM 0.076 0.651 −0.003 0.984
SBP −0.106 0.490 0.003 0.982
DBP −0.007 0.963 0.222 0.138
FPG −0.115 0.451 −0.066 0.664
HbA1c 0.145 0.341 0.738 <0.001 <0.001
LDL-C 0.137 0.383 0.420 0.005 0.701
TG 0.156 0.319 0.202 0.188
HDL-C 0.024 0.880 −0.137 0.374
AST 0.073 0.660 0.044 0.790
ALT 0.002 0.988 0.232 0.120
sCPR 0.222 0.152 0.108 0.542
Insulin dose 0.345 0.023 0.027 −0.078 0.617
Insulin dose U/kg 0.022 0.152 −0.102 0.509
Eating behavior −0.078 0.731 0.126 0.576
Previous treatment
Insulin 0.118 0.441 −0.176 0.242
BG −0.153 0.316 −0.053 0.725
SU −0.098 0.521 −0.250 0.094 0.996
αGI −0.035 0.819 −0.006 0.969
TZD 0.190 0.212 −0.191 0.204
DPP4i 0.048 0.752 0.169 0.263
Glinide −0.060 0.697 0.161 0.285
Reduction of body weight or HbA1c from baseline to 2 year was analyzed with baseline clinical parameters.
BMI; body mass index, WC; waist circumference, DM; diabetes mellitus, SBP; systolic body pressure; DBP diastolic body pressure, FPG; fasting plasma glucose,
HbA1c; glycated hemoglobin, LDL-C; low-density lipoprotein-cholesterol, TG; triglycerides, HDL-C; high-density lipoprotein-cholesterol, AST; aspartate aminotransferase,
ALT; alanine aminotransferase, sCPR; serum C-peptide immunoreactivity, BG; biguanide, SU; Sulfonylurea, αGI; α-glucosidase inhibitor, TZD; thiazolidinedione, DPP4i;
dipeptidyl peptidase-4 inhibitor.
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energy intake and body weight [15,16]. Our previous stud-
ies demonstrated that liraglutide improved eating behavior
in obese type 2 diabetes subjects until 6 months after lira-
glutide introduction [10,11]. As shown in Table 3, reduc-
tion of body weight was correlated positively with the
baseline scores of eating behavior in patients whose com-
bined anti-diabetic agents were unchanged for 1 year.
Present study suggests that liraglutide effectively reduces
body weight especially in obese patients with the disor-
dered eating behavior.
As in Figure 1, 46 patients (53.5%) resulted in the
amelioration of both body weight and glycemic control.
However, 23 patients (26.7%) revealed weight reductionbut deterioration of glycemic control, while 12 patients
(14.0%) showed improvement of glycemic control but
weight gain. These results may imply that liraglutide-
mediated ameliorations of body weight and glycemic
control are independent and possibly by different mech-
anisms in GLP-1 actions. Fadini et al. recently reported
in 166 patients (the average follow-up time: 9.4 months,
the average daily dose of liraglutide at 16 months:
1.37 mg/day) that significant determinants of weight re-
duction or glycemic control were baseline BMI, or base-
line HbA1c and previous insulin use, respectively [17].
Similar to their report, in the current study, significant
determinants for the reduction of body weight or HbA1c
from baseline to 2 year were baseline BMI and insulin
Inoue et al. Diabetology & Metabolic Syndrome 2014, 6:95 Page 8 of 9
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and current studies show that baseline BMI and HbA1c
may be important predictors for weight reduction and gly-
cemic control, respectively, before liraglutide therapy.
Aiming at body weight reduction, especially in obese sub-
jects with insulin therapy, the switch to liraglutide treat-
ment may be more effective and beneficial in clinical use.
Several pleiotropic effects of GLP-1 receptor agonists
have been demonstrated. GLP-1 receptor activation has
revealed the cardiovascular protection [18,19] and thus
GLP-1 receptor agonist may be considered a promising
new agent for the treatment of cardiovascular diseases
linked to obese type 2 diabetes [20,21]. GLP-1 receptor ag-
onists have been shown to suppress glucagon secretion in
mice and human [22]. Glucagon-mediated hyperglycemia
may be attenuated by liraglutide treatment, but glucagon
level was not monitored in present study. GLP-1 receptor
agonists have been also shown to improve other cardio-
metabolic parameters such as lipid profile and blood pres-
sure following 5-10% weight reduction [23]. Similar to
previous reports [23,24], in present study, LDL-C was sig-
nificantly reduced at 6 and 12 months even under statin
treatment in 55% of patients. By using questionnaire for
eating behavior, we previously showed the significant re-
duction of preference for fat at 6 months after liraglutide
introduction, suggesting that the reduction of dietary fat
intake partly contributed to the decrease of LDL-C level.
Liraglutide treatment also showed the slight reduction of
hepatic enzymes (Figure 4), which may indicate the im-
provement of fatty liver.
Present study has several limitations. This study is an
observational study, not a randomized clinical trial
(RCT) study. Dosage of liraglutide and combination with
other glucose-lowering agents were depended on the at-
tending physicians.
In summary, long-term treatment with liraglutide ef-
fectively reduced both body weight and HbA1c, and also
improved lipid profile and liver enzymes in Japanese pa-
tients with type 2 diabetes. Significant independent de-
terminants of weight reduction were baseline BMI and
previous insulin therapy, suggesting that effect of liraglu-
tide on weight reduction is further expected in obese
type 2 diabetes patients with previous insulin therapy.
Longer-term randomized clinical trials are warranted to
more thoroughly elucidate the effect of liraglutide on
body weight and complications of metabolic syndrome.
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